Apogee Therapeutics, Inc. (NASDAQ: APGE ) develops biologics for immune and inflammatory ("I&I") conditions. The company’s pipeline includes innovative monoclonal antibodies, such as APG777, APG808, and APG990. Each of these is designed for specific pathways within the inflammatory response. APG777's initial indication is atopicMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in co ...